144 related articles for article (PubMed ID: 22947171)
1. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
Armstrong EP; Skrepnek GH; Sasane M; Snodgrass SM; Ballas SK
J Med Econ; 2013; 16(1):10-8. PubMed ID: 22947171
[TBL] [Abstract][Full Text] [Related]
2. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
[TBL] [Abstract][Full Text] [Related]
3. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
4. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
Blinder MA; Vekeman F; Sasane M; Trahey A; Paley C; Duh MS
Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
Keshtkaran A; Javanbakht M; Salavati S; Mashayekhi A; Karimi M; Nuri B
Transfusion; 2013 Aug; 53(8):1722-9. PubMed ID: 23241074
[TBL] [Abstract][Full Text] [Related]
6. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
Vekeman F; Sasane M; Cheng WY; Ramanakumar AV; Fortier J; Qiu Y; Duh MS; Paley C; Adams-Graves P
J Med Econ; 2016; 19(3):292-303. PubMed ID: 26618853
[TBL] [Abstract][Full Text] [Related]
7. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
McLeod C; Fleeman N; Kirkham J; Bagust A; Boland A; Chu P; Dickson R; Dundar Y; Greenhalgh J; Modell B; Olujohungbe A; Telfer P; Walley T
Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
[TBL] [Abstract][Full Text] [Related]
8. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.
Luangasanatip N; Chaiyakunapruk N; Upakdee N; Wong P
Clin Drug Investig; 2011; 31(7):493-505. PubMed ID: 21627338
[TBL] [Abstract][Full Text] [Related]
9. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
Payne KA; Rofail D; Baladi JF; Viala M; Abetz L; Desrosiers MP; Lordan N; Ishak K; Proskorovsky I
Adv Ther; 2008 Aug; 25(8):725-42. PubMed ID: 18704280
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
Tolley K; Oliver N; Miranda E; Migliaccio-Walle K; Bozkaya D; Li Q
J Med Econ; 2010; 13(3):559-70. PubMed ID: 20812793
[TBL] [Abstract][Full Text] [Related]
11. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
[TBL] [Abstract][Full Text] [Related]
12. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
Tsouana E; Kaya B; Gadong N; Hemmaway C; Newell H; Simmons A; Whitmarsh S; Telfer P
Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Sridharan K; Sivaramakrishnan G
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):641-650. PubMed ID: 29727586
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
Vichinsky E; Pakbaz Z; Onyekwere O; Porter J; Swerdlow P; Coates T; Lane P; Files B; Mueller BU; Coïc L; Forni GL; Fischer R; Marks P; Rofail D; Abetz L; Baladi JF
Acta Haematol; 2008; 119(3):133-41. PubMed ID: 18408362
[TBL] [Abstract][Full Text] [Related]
15. The effects of chelators on zinc levels in patients with thalassemia major.
Erdoğan E; Canatan D; Ormeci AR; Vural H; Aylak F
J Trace Elem Med Biol; 2013 Apr; 27(2):109-11. PubMed ID: 23164519
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis.
Qadah T
J Int Med Res; 2022 Dec; 50(12):3000605221143290. PubMed ID: 36562113
[TBL] [Abstract][Full Text] [Related]
18. Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy.
Alvarez O; Rodriguez-Cortes H; Robinson N; Lewis N; Pow Sang CD; Lopez-Mitnik G; Paley C
J Pediatr Hematol Oncol; 2009 Oct; 31(10):739-44. PubMed ID: 19734806
[TBL] [Abstract][Full Text] [Related]
19. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Wu D; Wen X; Liu W; Hu H; Ye B; Zhou Y
Drug Des Devel Ther; 2018; 12():1081-1091. PubMed ID: 29760547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]